Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 101

Sort by

Sort Order Select

Journal Articles

High-Throughput Functional Drug Screening and Genomic Analysis to Guide Individualized Therapy for Relapsed/Refractory Multiple Myeloma

David G. Coffey, MD, Andrew J. Cowan, MD, Timothy S Martins, PhD, Damian J. Green, MD, Edward N. Libby, III, MD, Rebecca W. Silbermann, MD, Sylvia Chien, Jin Dai, PhD, Alicia Morales, Niall Curley, Bret Gary Degraaff, BS, Ted A Gooley, PhD, Edus H. Warren, MD PhD, Pamela S. Becker, MD PhD

Blood (2019) 134 (Supplement_1): 1885.

https://doi.org/10.1182/blood-2019-125383

Published: 2019

Journal Articles

Mitochondrial Activity Identifies a Transcriptionally and Functionally Distinct Subset of Aged HSCs with Lineage-Balanced Output

Els Mansell, PhD, Valgardur Sigurdsson, PhD, Elitza Deltcheva, PhD, John Brown, PhD, Chela James, PhD, Kenichi Miharada, PhD, Shamit Soneji, PhD, Jonas Larsson, MD PhD, Tariq Enver, PhD

Blood (2019) 134 (Supplement_1): 2480.

https://doi.org/10.1182/blood-2019-124001

Published: 2019

Journal Articles

The Oral CDK9 Inhibitor, TP-1287, Is Active in Non-Clinical Models of Multiple Myeloma

Ethika Tyagi, PhD, Clifford Whatcott, PhD, Jason M Foulks, PhD, Adam Siddiqui-Jain, PhD, David J. Bearss, PhD, Steven L. Warner, PhD

Blood (2018) 132 (Supplement 1): 3269.

https://doi.org/10.1182/blood-2018-99-120047

Published: 2018

Journal Articles

The CDK9 Inhibitor, Alvocidib, Potentiates the Non-Clinical Activity of Azacytidine or Decitabine in an MCL-1-Dependent Fashion, Supporting Clinical Exploration of a Decitabine and Alvocidib Combination

Wontak Kim, Clifford Whatcott, PhD, Adam Siddiqui-Jain, PhD, Stephen Anthony, DO, David J. Bearss, PhD, Steven L. Warner, PhD

Blood (2018) 132 (Supplement 1): 4355.

https://doi.org/10.1182/blood-2018-99-119793

Published: 2018

Journal Articles

Voruciclib, an Oral, Selective CDK9 Inhibitor, Enhances Cell Death Induced By the Bcl-2 Selective Inhibitor Venetoclax in Acute Myeloid Leukemia

Daniel A Luedtke, BS, Yongwei Su, Holly Edwards, BS, Lisa Polin, PhD, Juiwanna Kushner, Sijana H Dzinic, PhD, Hai Lin, MD, Jeffrey W. Taub, MD, Yubin Ge, PhD

Blood (2018) 132 (Supplement 1): 1361.

https://doi.org/10.1182/blood-2018-99-118372

Published: 2018

Journal Articles

Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Relapsed/Refractory Acute Myeloid Leukemia (AML)

Joshua F Zeidner, MD, Tara L Lin, MD, Carlos E Vigil, MD, Andrew Dalovisio, MD, Eunice S. Wang, MD, Moshe Yair Levy, MD, Mark G. Frattini, MD PhD, Daniel J. Lee, MD, Pau Montesinos, MD PhD, Juan Miguel Miguel Bergua Burgues, Jeffrey R. Schriber, MD, Stephen Anthony, DO, David J. Bearss, PhD, B. Douglas Smith, MD

Blood (2018) 132 (Supplement 1): 30.

https://doi.org/10.1182/blood-2018-99-115018

Published: 2018

Journal Articles

Integration of Functional Ex Vivo Drug Testing and Molecular Profiling Reveals Novel Vulnerabilities in CMML

Tea Pemovska, PhD, Gregory Ian Vladimer, PhD, Vitaly Sedlyarov, PhD, Emir Hadzijusufovic, DVM, Karoline Veronika Gleixner, MD, Alexandra Keller, MSc, Berend Snijder, PhD, Nikolaus Krall, PhD, Oscar Lopez de la Fuente, BSc, Mathias A Schneeweiss, MD, Wolfgang R. Sperr, MD, Paul Knöbl, MD PhD, Klaus Geissler, MD, Philipp Bernhard Staber, MD PhD, Ulrich Jaeger, MD, Peter Valent, MD, Giulio Superti Furga, PhD

Blood (2017) 130 (Supplement 1): 4227.

https://doi.org/10.1182/blood.V130.Suppl_1.4227.4227

Published: 2017

Journal Articles

Alvocidib Enhances Venetoclax Sensitivity in Unfavorable-Risk Multiple Myeloma Cells In Vitro and In Vivo

Liang Zhou, PhD, Yu Zhang, PhD, Deepak Sampath, PhD, Joel D. Leverson, PhD, Yun Dai, MD, Maciej Kmieciak, Matthew Nguyen, Robert Z. Orlowski, MD PhD, Steven Grant, MD

Blood (2017) 130 (Supplement 1): 2540.

https://doi.org/10.1182/blood.V130.Suppl_1.2540.2540

Published: 2017

Journal Articles

CDK7 Inhibitor THZ1 Inhibits Glycolytic Metabolism By Suppressing HIF1α Activity in Chronic Lymphocytic Leukemia

Shuchao Qin, MBBS, Austin Young Shull, Qimei Han, MBBS, Lirong Pei, Farrukh T. Awan, MD MS, Wei Xu, Jianyong Li, MD PhD, Huidong Shi

Blood (2017) 130 (Supplement 1): 3811.

https://doi.org/10.1182/blood.V130.Suppl_1.3811.3811

Published: 2017

Journal Articles

A Decade of Drug Development through Phase-1 Trials; Systematic Review of Literature for Novel Drugs and Targets in Multiple Myeloma

Imad Ud Deen, MBBS, Muhammad Umar Khalid, MD, Atlantis Dawn Russ, MD PhD, Anh Hua, BS, Ahmad Iftikhar, MD, Adeela Mushtaq, MD, Ahmad Safdar, BS, Ali McBride, PharmD,MS, Faiz Anwer, MD

Blood (2017) 130 (Supplement 1): 5399.

https://doi.org/10.1182/blood.V130.Suppl_1.5399.5399

Published: 2017

Journal Articles

The CDK7 Inhibitor THZ1 Alters RNA Polymerase Dynamics at the 5' and 3' Ends of Genes

Shilpa Sampathi, PhD, Pankaj Acharya, PhD, Yue Zhao, PhD, Jing Wang, PhD, Kristy Stengel, PhD, Qi Liu, PhD, Michael R. Savona, MD, Scott Hiebert, PhD

Blood (2017) 130 (Supplement 1): 1195.

https://doi.org/10.1182/blood.V130.Suppl_1.1195.1195

Published: 2017

Journal Articles

Alvocidib Potentiates the Activity of Venetoclax in Preclinical Models of Acute Myeloid Leukemia

Clifford J. Whatcott, PhD, James M Bogenberger, PhD, Wontak Kim, Hillary Haws, Nanna Hansen, M.S., Devora Delman, B.S., Lisa Sproat, MD MSW, Jeanne Palmer, MD, Ruben A. Mesa, MD, Peter Peterson, PhD, Adam Siddiqui-Jain, PhD, Steven Weitman, MD PhD, David J. Bearss, PhD, Steven L. Warner, PhD, Raoul Tibes, MD PhD

Blood (2016) 128 (22): 1652.

https://doi.org/10.1182/blood.V128.22.1652.1652

Published: 2016

Journal Articles

Selective Targeting Cyclin-Dependent Kinase-9 (CDK9) Downmodulates c-MYC and Induces Apoptosis in Diffuse Large B-Cell Lymphoma (DLBCL) Cells

Taylor Rowland, Cody Paiva, BS, Joelle Rowley, Andy Chen, MD PhD, Lisa Drew, PhD, Peter Hurlin, Bill H. Chang, MD PhD, Alexey V Danilov, MD PhD

Blood (2016) 128 (22): 289.

https://doi.org/10.1182/blood.V128.22.289.289

Published: 2016

Journal Articles

Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells

Cody Paiva, BS, Claire Godbersen, Stephen E Spurgeon, MD, Sreesha Srinivasa, Jennifer R Brown, MD PhD, Alexey V Danilov, MD PhD

Blood (2015) 126 (23): 1752.

https://doi.org/10.1182/blood.V126.23.1752.1752

Published: 2015

Journal Articles

Alvocidib Potentiates the Activity of Azacytidine in an MCL-1-Dependent Fashion

Wontak Kim, Katherine K. Soh, Jeremiah J. Bearss, Ye Sol Lee, Peter Peterson, PhD, Clifford J. Whatcott, PhD, Adam Siddiqui-Jain, PhD, Steven Weitman, MDPhD, James M Bogenberger, PhD, Raoul Tibes, MD PhD, David J. Bearss, PhD, Steven L. Warner, PhD

Blood (2015) 126 (23): 1343.

https://doi.org/10.1182/blood.V126.23.1343.1343

Published: 2015

Journal Articles

Alvocidib Potentiates the Activity of Cytarabine and Mitoxantrone through the Targeting of MCL-1 When Administered in a Time Sequential Regimen in AML

Wontak Kim, Brigham L. Bahr, Katherine K. Soh, Jeremiah J. Bearss, Ye Sol Lee, Peter Peterson, PhD, Clifford J. Whatcott, PhD, Adam Siddiqui-Jain, PhD, Steven Weitman, MDPhD, David J. Bearss, PhD, Steven L. Warner, PhD

Blood (2015) 126 (23): 3799.

https://doi.org/10.1182/blood.V126.23.3799.3799

Published: 2015

Journal Articles

Potential Synergy of TRAIL with CDK9 Inhibition in Selective Killing of HIV Infected Cell Lines and Primary CD4+ T Cells

David Kotlyar, MD, Constantinos Petrovas, PhD, Arik Cooper, PhD, David Ambrozak, MS, Christina Annunziata, MD PhD, Lidia Hernandez, PhD, Takuya Yamamoto, PhD, Sara Ferrando-Martinez, PhD, Joseph Casazza, MD PhD, Richard Koup, MD

Blood (2014) 124 (21): 4142.

https://doi.org/10.1182/blood.V124.21.4142.4142

Published: 2014

Journal Articles

Oncogenomic Screening Strategies to Identify Tumour Suppressor Genes on Chromosome 12 in Acute Myeloid Leukaemia

Jake Clayton, Joanna Cheng, Sarra Ryan, Christine J. Harrison, Paul Sinclair

Blood (2014) 124 (21): 898.

https://doi.org/10.1182/blood.V124.21.898.898

Published: 2014

Journal Articles

Evolution to Plasmablastic Lymphoma (PBL) after CAR-T Cell Therapy in a Case of SLL/CLL with Richter’s Transformation

Andrew Evans, MDPhD, Richard Burack, MDPhD, Paul G. Rothberg, PhD, David Porter, MD, Jane L. Liesveld, MD

Blood (2014) 124 (21): 5660.

https://doi.org/10.1182/blood.V124.21.5660.5660

Published: 2014

Journal Articles

Imbalance in Alternative Splicing of MCL-1 Inhibits Apoptosis in Diffuse Large B-Cell Lymphoma

Nicolle H Rekers, Laura M Moesbergen, Nathalie J Hijmering, Wim Vos, Joost Oudejans, Gert J. Ossenkoppele, Chris JLM Meijer, MD PhD, Saskia AGM Cillessen, PhD

Blood (2014) 124 (21): 5424.

https://doi.org/10.1182/blood.V124.21.5424.5424

Published: 2014

NARROW

High-Throughput Functional Drug Screening and Genomic Analysis to Guide Individualized Therapy for Relapsed/Refractory Multiple Myeloma

Mitochondrial Activity Identifies a Transcriptionally and Functionally Distinct Subset of Aged HSCs with Lineage-Balanced Output

The Oral CDK9 Inhibitor, TP-1287, Is Active in Non-Clinical Models of Multiple Myeloma

The CDK9 Inhibitor, Alvocidib, Potentiates the Non-Clinical Activity of Azacytidine or Decitabine in an MCL-1-Dependent Fashion, Supporting Clinical Exploration of a Decitabine and Alvocidib Combination

Voruciclib, an Oral, Selective CDK9 Inhibitor, Enhances Cell Death Induced By the Bcl-2 Selective Inhibitor Venetoclax in Acute Myeloid Leukemia

Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Relapsed/Refractory Acute Myeloid Leukemia (AML)

Integration of Functional Ex Vivo Drug Testing and Molecular Profiling Reveals Novel Vulnerabilities in CMML

Alvocidib Enhances Venetoclax Sensitivity in Unfavorable-Risk Multiple Myeloma Cells In Vitro and In Vivo

CDK7 Inhibitor THZ1 Inhibits Glycolytic Metabolism By Suppressing HIF1α Activity in Chronic Lymphocytic Leukemia

A Decade of Drug Development through Phase-1 Trials; Systematic Review of Literature for Novel Drugs and Targets in Multiple Myeloma

The CDK7 Inhibitor THZ1 Alters RNA Polymerase Dynamics at the 5' and 3' Ends of Genes

Alvocidib Potentiates the Activity of Venetoclax in Preclinical Models of Acute Myeloid Leukemia

Selective Targeting Cyclin-Dependent Kinase-9 (CDK9) Downmodulates c-MYC and Induces Apoptosis in Diffuse Large B-Cell Lymphoma (DLBCL) Cells

Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells

Alvocidib Potentiates the Activity of Azacytidine in an MCL-1-Dependent Fashion

Alvocidib Potentiates the Activity of Cytarabine and Mitoxantrone through the Targeting of MCL-1 When Administered in a Time Sequential Regimen in AML

Potential Synergy of TRAIL with CDK9 Inhibition in Selective Killing of HIV Infected Cell Lines and Primary CD4+ T Cells

Oncogenomic Screening Strategies to Identify Tumour Suppressor Genes on Chromosome 12 in Acute Myeloid Leukaemia

Evolution to Plasmablastic Lymphoma (PBL) after CAR-T Cell Therapy in a Case of SLL/CLL with Richter’s Transformation

Imbalance in Alternative Splicing of MCL-1 Inhibits Apoptosis in Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only